Goldman Sachs Initiates Coverage of Viatris (XTRA:VIA) with Neutral Recommendation

On June 6, 2025, Goldman Sachs initiated coverage of Viatris (XTRA:VIA) with a Neutral recommendation, while the average one-year price target is 9.75 €/share, representing a potential 162,454.00% upside from the latest closing price of 0.01 €/share. Despite this, projected annual revenue is expected to decrease by 31.28% to 9,848MM, and institutional ownership has slightly decreased by 2.62% to 1,158,925K shares, although the average portfolio weight dedicated to VIA by all funds increased by 22.74% to 0.18%.

Analysis

Goldman Sachs initiated coverage on Viatris (XTRA:VIA) with a Neutral recommendation on June 6, 2025, a stance that appears conservative given the average one-year analyst price target of 9.75 €/share, which implies an extraordinary 162,454.00% upside from its reported closing price of 0.01 €/share as of June 3, 2025. This exceptionally low current share price, juxtaposed with a projected annual non-GAAP EPS of 4.42 €, suggests a deeply distressed situation, potential data anomalies, or a market perceiving extreme risk, despite the EPS figure implying strong underlying profitability if achievable. Compounding the mixed outlook, Viatris faces a projected annual revenue decrease of 31.28% to 9,848MM €. Institutional sentiment also presents a nuanced picture: while the total number of institutional owners (1,653) and their aggregate shareholdings (1,158,925K shares) saw slight quarterly decreases of 1.90% and 2.62% respectively, the average portfolio weight of all funds dedicated to VIA increased by a significant 22.74% to 0.18%. Among notable shareholders, Price T Rowe Associates and Davis Selected Advisers increased their share counts by 21.19% and 3.66% respectively, though both reduced their portfolio allocations in VIA. Conversely, Pacer US Cash Cows 100 ETF reduced both its share count by 12.31% and its portfolio allocation. The general sentiment score of -0.25 (mildly negative) for Viatris and an overall 'speculative' tone from market signals further underscore the high uncertainty surrounding the company.

Key Decisions for Investors

• Given the extreme discrepancy between the current 0.01 € share price and the 9.75 € average target, investors should approach Viatris with extreme caution, recognizing the highly speculative nature and inherent volatility implied by such figures.
• Investors should thoroughly investigate the reasons behind the current depressed valuation and scrutinize the feasibility of achieving a 4.42 € non-GAAP EPS amidst a projected 31.28% revenue decline before considering any position.
• Despite the astronomical price target upside, Goldman Sachs' 'Neutral' initiation, declining revenue projections, and mixed institutional signals warrant a cautious stance; focus on understanding the cause of the current share price and validating fundamental recovery prospects.